explore -WSS

explore

author：entertainment 2025-09-28 00:52:18 - browse：236

Illumina said Monday afternoon that its board of directors had approved a spin-off of its cancer test subsidiary Grail, signaling that a nearly four-year-long, $8 billion saga will finally draw to a close this month.

Shares in the newly independent Grail are expected to be distributed on June 24, Illumina said in a statement. Illumina will retain a 14.5% stake in the company, which will trade under the ticker $GRAL.

It’s the second time Illumina has spun off Grail, which initially began as a unit within the DNA sequencing giant in 2015. Illumina turned it into an independent company the following year but then agreed to reacquire it for $8 billion in September 2020.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： ARCH Venture Partners is raising $3 billion for a life sciences fund

hotspot

WSS

Are embryos people? Reproductive medicine's future depends on the answer

Woodcock on FDA’s accelerated approval and her next chapter

Apple Vision Pro: A first look at health apps on the new VR headset

Childhood vaccination ad campaign launches in the U.K.

Neuroscience renaissance leads to new crop of psychiatric drugs

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Continuity nursing helped my family in our darkest PICU moments

Redefining sustainability for the pharmaceutical industry

Psychedelics group wrestles with new pharma identity

Are embryos people? Reproductive medicine's future depends on the answer

Psychedelics group wrestles with new pharma identity

Redefining sustainability for the pharmaceutical industry

Malaria cases in Florida and Texas: Here’s what you need to know

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Trump demands the U.S. pay no more for drugs than other countries … again

Apple Vision Pro: A first look at health apps on the new VR headset

entertainment

FDA drug safety: Singulair case shows systemic surveillance flaws

General Catalyst, Summa Health deal will turn on physician buy

Doctor of U.S. President Joe Biden says he is fit for duty

SAMSHA loosens regulations on methadone treatment centers

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Children’s Hospital revives plan for pedestrian bridge

hotspot

leisure time

hotspot

entertainment